Use of mTOR Inhibitors to Enhance T Cell Immune Responses

It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.

Patents:
US 20,110,129,496

Inventor(s): AHMED RAFI [US]; LARSEN CHRISTIAN P [US]; ARAKI KOICHI [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents

Share on      


CrowdSell Your Patent